Several biopharmaceutical and healthcare companies reported their second-quarter 2025 financial results and provided business updates. Avadel Pharmaceuticals (AVDL) reported net revenue of $68.1 million for its drug LUMRYZ™, marking a 64% increase compared to the same quarter in 2024. The company also posted a net income of $9.7 million and earnings per share of $0.10, surpassing estimates of $0.03 per share. Avadel highlighted a 63% increase in patients on LUMRYZ, reaching 3,100 as of June 30, 2025. The company achieved positive cash flow in the quarter and increased its cash, cash equivalents, and marketable securities by $15 million compared to March 31, 2025. Avadel raised its 2025 revenue guidance following these results. Other companies reporting second-quarter results include Prime Medicine, PMV Pharmaceuticals, Cormedix Inc., AvidXchange, Aveanna Healthcare Holdings, Nuvalent, Phathom Pharmaceuticals, Immunocore, Rapport Therapeutics, Akebia Therapeutics, Avalo, Black Diamond Therapeutics, Cabaletta Bio, Achieve Life Sciences, MBX Biosciences, RAPT Therapeutics, and Amylyx Pharmaceuticals. These reports collectively provide insights into the financial performance and business progress across the biopharmaceutical and healthcare sectors for the quarter ending June 30, 2025.